Clinical Trial

Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention

Study acronym: MATE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) after coronary intervention. Standard DAPT of aspirin plus ticagrelor will be given for the first 1 month after PCI. After 1 month, event-free subjects will be randomized at 1:1 ratio into receiving standard DAPT (DAPT) until 12months , or switch to ticagrelor monotherapy for another 5 months , and further de-escalated to monotherapy of clopidogrel for the last 6 months(SAPT).
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT04937699
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Acute Coronary Syndrome, Percutaneous Coronary Intervention
Enrollment 2,690 participants
Start Date 2023-03-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-07